BioNTech Investor Day Presentation Deck

Fix Vac Leveraging shared tumor-associated antigens for cancer treatment 5' Vaccine backbone with shared antigens THI ANTIGEN CASSETTE Backbone-optimized uridine mRNA (URNA) + Multi-antigen approach tailored to each indication Melanoma NY-ESO-1 Tyrosinase MAGE-A3 TPTE AAAA Poly(A) tail BNT111 encodes 4 tumor-associated antigens covering >90% of patients with cutaneous melanoma + HPV-E6 Lipoplex HPV-E7 T RNA-LPX formulation (IV) HPV16+ HNSCC HNSCC, head and neck squamous-cell carcinoma; HPV, human papilloma virus; NSCLC, non-small-cell lung cancer. TALL Th T BNT113 encodes 2 oncoproteins exclusively expressed in pre-malignant and malignant tissue || Prostate cancer KLK2 KLK3 ACPP HOXB13 NKX3-1 Fix Vac BNT112 encodes 5 related antigens specific to prostate cancer NUM 6666 Fixed vaccine combination against shared tumor-associated antigens mRNA cancer vaccines NSCLC Antigen 1 Antigen 2 Antigen 3. Antigen 4 Antigen 5 Antigen 6 BNT116 encodes 6 different NSCLC tumor-associated antigens AAAA AAAA AAAA AAAA AAAA AAAA BIONTECH 107

View entire presentation